Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-α production

被引:58
作者
Gasche, C
Grundtner, P
Zwirn, P
Reinisch, W
Shaw, SH
Zdanov, A
Sarma, U
Williams, LM
Foxwell, BM
Gangl, A
机构
[1] Univ Vienna, Dept Med 4, Div Gastroenterol & Hepatol, Vienna, Austria
[2] DNA Sci Inc, Fremont, CA 94555 USA
[3] NCI, Macromol Crystallog Lab, Frederick, MD 21702 USA
[4] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London, England
关键词
D O I
10.4049/jimmunol.170.11.5578
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-10-deficient mice exhibit spontaneous enterocolitis and other symptoms akin to Crohn's disease, indicating that IL-10 might regulate normal physiology in the gut. However, clinical trials with IL-10 in Crohn's disease were disappointing, although some patients showed healing of intestinal mucosa. This study searched for genetic polymorphisms within the IL-10 pathway. We decided to screen for mutations of the IL-10R1 cDNA in healthy volunteers and Crohn's disease patients and identified two novel variants: a serine 138-to-glycine (S138G) and a glycine 330-to-arginine (G330R) substitution. The allelic frequency in a European cohort was relatively high (16% for the S138G and 33% for the G330R), and S138G was in strong linkage disequilibrium with G330R. A similar allele frequency was found in a group of Crohn's patients. In IL-10R1 G330R-expressing monocytes, the inhibitory effect of IL-10 on TNF-alpha production was diminished, indicating that this variant may be a loss-of-function allele. No such difference was observed between haplotypes 4 (G330R only) and 7 (S138G and G330R). In addition, these IL-10R1 variants had no influence on the IL-10R1 expression density. Structural analysis of the S138G variant revealed that the substitution of S138G may interfere with binding of IL-10 to IL-10R1.
引用
收藏
页码:5578 / 5582
页数:5
相关论文
共 41 条
[31]   Interleukin-10 receptor signaling through the JAK-STAT pathway - Requirement for two distinct receptor-derived signals for anti-inflammatory action [J].
Riley, JK ;
Takeda, K ;
Akira, S ;
Schreiber, RD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) :16513-16521
[32]   Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease [J].
Schreiber, S ;
Fedorak, RN ;
Nielsen, OH ;
Wild, G ;
Williams, CN ;
Nikolaus, S ;
Jacyna, M ;
Lashner, BA ;
Gangl, A ;
Rutgeerts, P ;
Isaacs, K ;
Van Deventer, SJH ;
Koningsberger, JC ;
Cohard, M ;
LeBeaut, A ;
Hanauer, SB .
GASTROENTEROLOGY, 2000, 119 (06) :1461-1472
[33]   The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor [J].
Spencer, SD ;
Di Marco, F ;
Hooley, J ;
Pitts-Meek, S ;
Bauer, M ;
Ryan, AM ;
Sordat, B ;
Gibbs, VC ;
Aguet, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :571-578
[34]   CHOICE OF STATS AND OTHER SUBSTRATES SPECIFIED BY MODULAR TYROSINE-BASED MOTIFS IN CYTOKINE RECEPTORS [J].
STAHL, N ;
FARRUGGELLA, TJ ;
BOULTON, TG ;
ZHONG, Z ;
DARNELL, JE ;
YANCOPOULOS, GD .
SCIENCE, 1995, 267 (5202) :1349-1353
[35]   Interleukin-10 (IL-10) genotypes in inflammatory bowel disease [J].
Tagore, A ;
Gonsalkorale, WM ;
Pravica, V ;
Hajeer, AH ;
McMahon, R ;
Whorwell, PJ ;
Sinnott, PJ ;
Hutchinson, IV .
TISSUE ANTIGENS, 1999, 54 (04) :386-390
[36]   Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils [J].
Takeda, K ;
Clausen, BE ;
Kaisho, T ;
Tsujimura, T ;
Terada, N ;
Förster, I ;
Akira, S .
IMMUNITY, 1999, 10 (01) :39-49
[37]  
TAN JC, 1993, J BIOL CHEM, V268, P21053
[38]   Detection of polymorphisms within the human IL10 receptor cDNA gene sequence by RT-PCR RFLP [J].
Tanaka, Y ;
Nakashima, H ;
Otsuka, T ;
Nemoto, Y ;
Niiro, H ;
Yamaoka, K ;
Ogami, E ;
Arinobu, Y ;
Tachida, H ;
Imamura, T ;
Niho, Y .
IMMUNOGENETICS, 1997, 46 (05) :439-441
[39]  
TERWILLIGER JD, HDB HUMAN GENETIC LI, P188
[40]   Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease [J].
vanDeventer, SJH ;
Elson, CO ;
Fedorak, RN .
GASTROENTEROLOGY, 1997, 113 (02) :383-389